IMUGENE LIMITED — Investor Presentation 2021

Aug 4, 2021

==> picture [178 x 76] intentionally omitted <==

ASX : I MU

IMUGENE & CELULARITY RESEARCH PARTNERSHIP

5[th] August 2021

Disclaimer

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

==> picture [106 x 45] intentionally omitted <==

1. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

2. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change

3. International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

2

Introduction to Imugene

Imugene is a biotech company 2 0 1 8 headquartered in Australia and Licensed extensive B cell portfolio and platform from publicly traded on the Australian OSU and Mayo Clinic M A Y 2 0 2 1 Securities Exchange (ASX:IMU) comprising of PD1, HER1, Licensed onCARlytics HER2, HER3, VEGF, from City of Hope IGF-1R, CD28 invented by Dr Y Fong, Dr S Priceman & 2 0 1 5 Dr A Park 2 0 1 9 Leslie Chong 2 0 1 3 Completed the from Genentech 2 0 1 7 acquisition of a prolific Paul Hopper built joined Imugene HER-Vaxx, our HER-2 oncolytic virus from Imugene around a targeted B Cell City of Hope invented by technology that originated from the Immunotherapy Dr Yuman Fong entered the clinic Medical University of Vienna

==> picture [106 x 45] intentionally omitted <==

A U G 2 0 2 1

Strategic Partnership with Celularity

==> picture [84 x 54] intentionally omitted <==

==> picture [105 x 23] intentionally omitted <==

3

Partnership Highlights

==> picture [106 x 45] intentionally omitted <==

• Strategic Research Partnership with Celularity Inc. (Nasdaq: CELU) for the Treatment of Solid Tumors

• Collaboration will explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytic) and Celularity’s CD-19-targetting chimeric antigen receptor (CAR) placental-derived T cell therapy, CYCART-19

• CYCART-19 is a placental-derived T cell therapy engineered with a CAR that is cryopreserved, allogeneic and available offthe-shelf that clinicians can access on demand, enabling repeat dosing/multiple cycles as required in an outpatient setting

• Celularity’s off-the-shelf allogeneic CYCART-19 therapy has shown increased T-cell growth with continuous killing of tumor cells in vivo

• CYCART-19 demonstrates significantly reduced tumor burden and survival benefit compared to adult blood-derived CD19 CAR-T cells in vivo

• Imugene’s novel strategy to treat solid tumors uses onCARlytics to prime the tumor cells for destruction by eliciting the expression of a validated tumor marker, CD19, then used as a target for CD19-CAR-T cellular therapy

• Nonclinical in vitro and in vivo combination studies with CYCART-19 and onCARlytic to commence in 2021

4

• Dr. Hariri is the chairman, founder, and chief executive officer of Celularity, Inc., (NASDAQ: CELU).

• Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri has served on numerous public boards including Cryoport (NASDAQ:CYRX).

• Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). Dr. Hariri and his team of scientists were the first to obtain FDA approval to use its cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy to treat COVID-19 infected adults.

==> picture [106 x 45] intentionally omitted <==

Robert (Bob) J. Hariri, M.D., Ph.D.

Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace.

• He holds over 170 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.

• Dr. Hariri was the recipient of the Pontifical Medal for Innovation awarded by Pope Francis in 2018 for his discovery of placental stem cells and advances in immunotherapy and regenerative medicine. Dr. Hariri has received the Thomas Alva Edison Award for invention, in 2007, 2011 and 2021, and is a recipient of the Children’s Brain Tumor Foundation’s Fred J. Epstein Lifetime Achievement Award. Dr. Hariri was recipient of the Genius of New Jersey Award in 2019 and Pioneer in Medicine and Golden Axon Awards in 2021.

• Dr. Hariri is an Adjunct Professor of Neurosurgery and member of the Board of Overseers of the Weill Cornell Medical. He is a member of the X PRIZE Foundation scientific advisory board for the Archon X PRIZE for Genomics. Dr. Hariri is a trustee and vice-chair of the Liberty Science Center. In 2010 he was appointed a Commissioner of Cancer Research by New Jersey Governor Chris Christie.

• Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He was a surgical resident and fellow in neurosurgery at The New York Hospital-Cornell Medical Center and served as an Assistant Professor of Neurosurgery and Associate Research Professor of Surgery at Cornell and Co-director of the Aitken Laboratory in Neurosurgery.

• When he is not in the laboratory or the corporate boardroom, Dr. Hariri is a jet-rated, high performance commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft. He has also produced several feature films, as well as documentaries on global societal issues.

5

==> picture [480 x 112] intentionally omitted <==

THE NEXT EVOLUTION IN CELLULAR MEDICINE

CELULARITY: COMPANY HISTORY

Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation

==> picture [73 x 73] intentionally omitted <==

Celularity and Celularity GX Acquisition and GX FIH Genetically Corp. Announce close cryopreserved Allogeneic -modified Merger merger and Allogeneic Celgene & allogeneic Placental NK cell Agreement to Celularity Placental Juno formed from placentalPluripotent therapy Create a begins to Anthrogenesis MesenchymalTherapeutics Celgene derived NK Cell program Publicly Listed trade on C O R P O R A T I O N like Stromal autologous Cell cell therapy program $100M launched Leader in Nasdaq Founded by Cells in CAR-T Therapeutics product launched Series B-1 (CYNK- Allogeneic under Dr. Robert Hariri Crohn’s, DFU collaboration spin-out (CYNK-001) (APPL-001) Financing 101) Cellular Therapy "CELU" 2000 2002 2003 2005 2015 2016 2017 2018 2019 2020 2021 Anthrogenesis Celgene & FIH $45M $210M Placental IND Safe IND Safe to Placental Fast Track Orphan acquired bluebird bio allogeneic Series A Series B Exosome to Proceed T-cell/CAR-T Designation Drug by Celgene, autologous placentalFinancing Financing program Proceed CYNK-001 in program by the FDA Designation becomes CAR-T derived NK launched CYNK-001 COVID-19 launch for CYNKfor CYNKCelgene Cellular collaboration cell therapy (pExo) in GBM (CyCART-19) 001 in the 001 in the Therapeutics product Treatment Treatment (Placental of of Malignant NK-007) Recurrent Gliomas GBM

CLINICAL MILESTONE

KEY: CORPORATE MILESTONE

FINANCIAL MILESTONE

Page 7

About Celularity

==> picture [78 x 78] intentionally omitted <==

Next Evolution in Off-the-shelf Allogeneic Cellular Therapies, at Greater Scale & Quality with Attractive Economics

==> picture [311 x 426] intentionally omitted <==

To harness the placenta’s unique biology and ready availability to develop therapeutic solutions

Lead the evolution in placental-derived therapeutics: advance the discovery of the placenta as a limitless, renewable source of neonatal cells, which are biologically preferred to cells from adult bone marrow or peripheral blood

: Target large markets with high unmet need broad therapeutic application including cancer, degenerative, and infectious diseases

: Develop safe and effective therapies

leverage inherent advantages of placental-derived cells to produce uniform, scalable and optimized cellular therapies

: Deliver off-the-shelf, cost effective therapies

cryopreserved allogeneic cellular therapies that clinicians can access on demand and off-the-shelf, enabling repeat dosing/multiple cycles as required in an outpatient setting

Page 8

CELULARITY IMPACT™PLATFORM

Capitalizing on the Benefits of Placental-Derived Cells to Target Multiple Diseases

==> picture [73 x 73] intentionally omitted <==

INHERENT ADVANTAGES OF PLACENTAL-DERIVED CELLS

• ü Abundant and evergreen starting cell source for allogeneic off-the-shelf therapies

• ü High expandability, persistence and stemness

• ü Can be administered off-the-shelf, as this abundantly available source material possesses a low potential to provoke an immune response

• ü No requirement for matching between a patient and donor

• ü Innate stemness represent a flexible foundation that can be repeatedly genetically modified without losing potency

Celularity IMPACT™ SOLID ( I mmuno- M odulatory TUMORS Placental-derived A llogeneic C ell T herapy)

==> picture [209 x 199] intentionally omitted <==

----- Start of picture text -----

HEMATOLOGICAL
MALIGNANCIES
DEGENERATIVE
DISEASES
----- End of picture text -----

INFECTIOUS DISEASE

• ü 100-100K doses of therapeutic per placenta

Page 9

PIPELINE Overview

==> picture [890 x 385] intentionally omitted <==

----- Start of picture text -----

CELL TYPE PROGRAM INDICATION 2021 2022
Program Milestones
B-Cell IND
CAR-T CyCART-19 Malignancies Submission Phase I Phase II CYNK-001
§ 2H21: Dose Selection & Initiation
of Expansion Cohorts (AML)
Unmodified § 2H21: Establish Phase II Dose
CYNK-001 Acute Myeloid
Natural Phase I Phase II (GBM)
(cryopreserved) Leukemia (AML)
Killer Cell
CYNK-101
Genetically § 2H21: IND Submission
CYNK-101 HER2+ IND
Modified + mAb Gastric Cancer Submission Phase I/IIa Phase II § 2H21: Phase I/IIa Study Start
Natural Killer Cell
CyCART-19
§ 2H21: IND Submission Expected
Unmodified
Natural CYNK-001 Glioblastoma Phase I/IIa Phase II § 2H21: Phase I Study Start
(cryopreserved) Multiforme (GBM)
Killer Cell
APPL-001
§ 1H22: Phase I/IIa Study Start
Placental
Crohn’s IND
Mesenchymal-like APPL-001 Submission Phase I/IIa
Disease
Stromal Cell
----- End of picture text -----

Program Milestones

• § 2H21: Dose Selection & Initiation of Expansion Cohorts (AML)

• § 2H21: Establish Phase II Dose (GBM)

• § 2H21: IND Submission Expected

2 Upcoming IND Submissions (2021E) & 5 Clinical Trials by end of 2021

CONFIDENTIAL

Page 10

CyCART-19 OVERVIEW Celularity Approach and Advantages

RATIONALE

• § Rationale for greater stemness, expandability, persistence

• § Abundant renewable starting cell source for allogeneic therapies

• § Potential for improved safety profile due to immunological naivety

KEY HIGHLIGHTS

• § Celularity has established a robust process to obtain placental T naive/scm population as source materials to produce off-the-shelf, highly scalable CyCART-19 cells

• § CyCART-19 demonstrates stem cell memory characteristics as evidenced by greater in vivo persistence and durable antitumor activity in preclinical models

• § Strong pre-clinical evidence of anti-tumor activity

• CyCART-19 cells outperform adult blood-derived CART cells by significantly greater persistence and longer survival in preclinical studies

• § Early data suggesting no signs of GvHD

• § Note: If Phase 1 successful, Celularity plans to pursue a Phase 2 basket trial across major B-cell malignancies (subject to FDA discussions)

CLINICAL PLAN

• § 2H21: IND Submission Expected

• § 1H22: Phase I Study Start

MANUFACTURING COMPLEXITY		CAR-T THERAPIES	CAR-T THERAPIES	CAR-T THERAPIES
	Cell Therapy Technology Scorecard	AUTOLOGOUS	OTHER ALLOGENEIC	CELULARITY CyCART-19
	Source Procurement Non-invasive Collection / Reliable Procurement	O	O	P
	Lower COGs Standardized, Scalable Manufacturing	O	P	P
	Starting Material Consistent Quality and Phenotype	O	O	P
	Ability to Readily Expand While Maintaining a Less Differentiated Phenotype	O	O	P
	“Off-the-Shelf” Treatment	O	P	P
	Ability to Re-dose Patients (if Necessary)	O	P	P

• § 2H22: Phase II Study Start

Page 11

CyCART-19 DEMONSTRATES GREATER ANTI-LYMPHOMA ACTIVITIES & SURVIVAL Enhanced Efficacy & Persistence, Prolonged Immune Attack upon Tumor Recharging

==> picture [592 x 352] intentionally omitted <==

----- Start of picture text -----

Survival CyCART: Durable Persistence
1 0 0
8 0 R e - c h a l l e n g e
( d 1 2 2 )
6 0
4 0
2 0
0
0 3 0 6 0 9 0 1 2 0 1 5 0 1 8 0 2 1 0
D a y s
l
a
i v
v
r
u
S
----- End of picture text -----

==> picture [280 x 299] intentionally omitted <==

• § CyCART-19 demonstrates significantly reduced tumor burden and survival benefit compared to adult blood-derived CD19 CAR-T cells

• § CyCART-19 eliminated tumor and resulted in 100% survival out to 120 days

• § CyCART-19 “ memory” characteristics demonstrated via:

– Extended survival out to 215 days upon tumor re-challenge on Day 122

• Differentiated persistence at end of study to elicit prolonged antitumor activities

Source: Celularity Data

Page 12

The CAR T Solid Tumour Challenge & Imugene’s Solution

Chimeric Antigen Receptor (CAR) T cell therapy has had limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen CD19.

CD19 CAR T Cells

CD19 Targeting domain

==> picture [106 x 45] intentionally omitted <==

N E W C O N C E P T

Utilise OV’s as a delivery vector to deliver CD19 antigen to solid tumour cells

Engineer Imugene’s CF33 to infect solid tumour cells and insert CD19 transgene to enable presentation of CD19 over the tumour cells during tumour cell infection, onCARlytics (CF33-CD19)

Combination use of autologous or allogeneic CD19 CAR Ts with onCARlytics (CF33-CD19) presents CD19 targets on solid tumours

Solid Tumour

OV generated CD19

13

Mechanism of Action: How does it work?

==> picture [221 x 340] intentionally omitted <==

----- Start of picture text -----

1
4
2
3
----- End of picture text -----

==> picture [106 x 45] intentionally omitted <==

onCARlytics makes solid tumours “seen” by CD19 directed CAR T

1. OnCARlytics infects tumour cells

2. Virus replication and production of CF33-CD19 on the cell surface enabling CD19 CAR T cell targeting

3. Tumour cell lysis leads to viral particle release and the combination promotes endogenous immune cell recruitment to tumours

4. Released viral particles re-initiate virus infection of surrounding tumour cells.

14

onCARlytics delivers CAR Targets to “ targetless ” solid tumours

==> picture [461 x 157] intentionally omitted <==

----- Start of picture text -----

J2R
Vacci ni a O ncol yti c Virus
CF33-(SE)hCD19t P SE Vaccin ia Vir us
hCD19t
CD19
DAPI
MOI 0.025 MOI 1 MOI 0 CD19t
----- End of picture text -----

onCARlytics (CF33-CD19) infects a wide array of solid tumour cell lines, with dose-dependent CD19 cell surface expression

==> picture [466 x 156] intentionally omitted <==

----- Start of picture text -----

100
Capan-1 (pancreas)
80
DU145 (prostate)
60
OV90 (ovarian)
40
Pan c -1 (pancrea s)
20
UM- SCC -1 (head and neck)
0
UM-S CC -47 (head and neck)
U25 1 T ( glioma)
Multiplicity if infection
0.001 0.01 0.1 1 10
CD19t (%)
----- End of picture text -----

==> picture [106 x 45] intentionally omitted <==

Combination of onCARlytics (CF33-CD19) and ~~CD19~~ -CAR T cells promotes tumour regression in ~~xenog~~ raft model of TNBC

==> picture [244 x 296] intentionally omitted <==

----- Start of picture text -----

i.t.10M i.t. 5M Mock or
pfu OV19t CD19-CAR T cells
s.c.
MDA-MB-468
OV T cells
600
400
200
p < 0.05
0
0 20 40 60 80
Days post tumor injection
No treatment OV19t alone
Mock alone OV19t + Mock
CAR alone OV19t + CAR
)
3
Tumor Volume (mm
----- End of picture text -----

15

Park et al. Science Translational Medicine 2020

==> picture [106 x 45] intentionally omitted <==

onCARlytics and CyCART-19 - a perfect match!

==> picture [802 x 275] intentionally omitted <==

----- Start of picture text -----

CyCART-19
----- End of picture text -----

1. 1. 1. 1. CD19 ONCOLYTIC VIRUS CD19 ONCOLYTIC VIRUS CyCART-19 CELLS CANCER CELLS DIE INFECTS SOLID CANCER CAUSES THE SOLID RECOGNISE THE “CD19 CELLS CANCER CELLS TO GROW FLAGS” AND ATTACK THE “CD19 FLAGS” CANCER CELL

16

Milestones

==> picture [106 x 45] intentionally omitted <==

==> picture [16 x 17] intentionally omitted <==

Technology	Milestone
onCARlytics	1st Patient Dosed Monotherapy	~~Next 12~~-24 months
onCARlytics	FDA IND Clearance
PD1-Vaxx	Combination RP2D
onCARlytics	GLP Toxicology Study
VAXINIA	1st Patient Dosed
PD1-Vaxx	Expansion combination study FPI
HER-Vaxx	Phase 2 Final Analysis
VAXINIA	FDA IND Clearance
onCARlytics	FDA Pre-IND Meeting
PD1-Vaxx	Maximum Feasible Dose Identified
HER-Vaxx	OS Endpoint Met
onCARlytics	GMP manufacturing for pre-clinical toxicology & Phase 1 study
CHECKvacc	TNBC IST 1st Patient Dosed
onCARlytics	Strategic partnership with Celularity on CD19 CART
CHECKvacc	FDA IND Clearance

17

==> picture [178 x 76] intentionally omitted <==

Leslie Chong Managing Director & CEO leslie.chong@imugene.com